ImmuPharma plc (LON:IMM – Get Free Report) shot up 24.7% on Friday . The company traded as high as GBX 3.60 ($0.04) and last traded at GBX 3.27 ($0.04). 3,967,846 shares changed hands during mid-day trading, a decline of 83% from the average session volume of 22,889,953 shares. The stock had previously closed at GBX 2.63 ($0.03).
ImmuPharma Price Performance
The company has a fifty day moving average price of GBX 1.56 and a 200 day moving average price of GBX 1.68. The company has a market cap of £12.53 million, a PE ratio of -301.00 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- What is the Hang Seng index?
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
- Investing in Travel Stocks Benefits
- Top Growth Picks: 3 Low-Cost Stocks That Could Double in Value
- How to Invest in Biotech Stocks
- Is Johnson & Johnson Stock Set to Reward Long-Term Holders?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
